OMEPRAZOLE OR RANITIDINE PLUS METOCLOPRAMIDE FOR PATIENTS WITH SEVERE EROSIVE ESOPHAGITIS - A COST-EFFECTIVENESS ANALYSIS

被引：21

作者：

BLOOM, BS

HILLMAN, AL

LAMONT, B

LISS, C

SCHWARTZ, JS

STEVER, GJ

机构：

[1] Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania, 19104-6020

[2] Covalent Research Alliance, Wayne, Pennsylvania

[3] Merck & Co. Inc., West Point, Pennsylvania

来源：

PHARMACOECONOMICS | 1995年 / 8卷 / 04期

关键词：

D O I：

10.2165/00019053-199508040-00008

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

The objective of this study was to evaluate the clinical and economic effects of 2 clinical strategies for treating severe (grade II and above) erosive oesophagitis or poorly responsive gastro-oesophageal reflux disease. A single-blind, randomised controlled trial of up to 8 weeks' duration was undertaken comparing omeprazole with ranitidine plus metoclopramide in patients with severe and symptomatic erosive oesophagitis (endoscopic grade II and above). Two cost-effectiveness ratios were calculated: cost per healed patient and cost per symptom-free day. The study perspective was that of the payer or insurer of medical care. Healing rates were significantly higher among omeprazole-treated patients than among those who received ranitidine/metoclopramide de at 4 weeks (68.5% vs 30.4%; p < 0.01) and overall (81.5% vs 45.7%; p < 0.01). Overall, mean gastrointestinal-related direct medical costs per healed patient were lower for the omeprazole group ($US189.60) than for the ranitidine/metoclopramide group ($US319.28). The incremental cost of an additional cure with omeprazole compared with ranitidine/metoclopramide was $US24.05. The overall average cost per symptom-free day was lower in the omeprazole group ($US7.88) than in the ranitidine/metoclopramide group ($US10.81). The incremental cost to obtain an additional symptom-free day with omeprazole, compared with ranitidine/metoclopramide, was $US1.41. In conclusion, superior efficacy at comparable cost is achieved by omeprazole compared with ranitidine/metoclopramide in the treatment of patients with severe erosive oesophagitis.

引用

页码：343 / 349

页数：7

共 15 条

[1] Hetzel D.J., Dent J., Reed W.D., Et al., Healing and relapse of severe peptic esophagitis after treatment with omeprazole, Gastroenterology, 95, (1988)
[2] Sandmark S., Caelsson R., Fausa O., Et al., Results of a double-blind, randomized, Scandinavian multicenter study, Scand J Gastroenterol, 23, (1988)
[3] Zeitoun P., de Desjars Keranroue N., Isai J.P., Omeprazole versus ranitidine in erosive esophagitis, Lancet, 1, 2, (1987)
[4] Sontag S.J., Hirschowitz B.I., Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter StUdy, Gastroenterology, 102, (1992)
[5] Vantrappen G., Rutgeerts L., Schurmans P., Et al., Omeprazole (40mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis, Dig Dis Sci, 33, (1988)
[6] Klinkenberg-Knol E.C., Jansen J.M., Peston H.P., Et al., Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis, Lancet, 1, (1987)
[7] Blum A.L., Riecken E.O., Dammann H.G., Et al., Comparison of omeprazole and ranitidine in the treatment of reflux esophagitis [letter], N Engl J Med, 314, (1986)
[8] Havelund I., Laursen L.S., Skoubo-Kristensen B., Et al., Omeprazole and ranitidine in treatment of reflux oesophagitis: double-blind comparative trial, BMJ, 296, pp. 89-92, (1988)
[9] Hillman A.L., Bloom B.S., Fendrick A.M., Et al., Cost and quality effects of alternative treatments for persistent gastro-esophageal reflux disease, Arch Intern Med, 152, (1992)
[10] Bate C.M., Richardson P.D.I., Symptomatic assessment and cost-effectiveness of treatment for reflux oesophagitis: comparisons of omeprazole and histamine H2-receptor antagonists, Br J Med Econ, 2, pp. 37-48, (1992)

← 1 2 →